Minerva Neurosciences, Inc.
NASDAQ:NERVBiotechnology
Healthcare
$2.18 -6.49%
-$0.30 today
- Market cap
- $108.64M
- Beta
- -0.11
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$8.46
52W Low $1.76High $12.46
Volume 0.28M
Average 0.21M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$15.10M
FY 2025 · Annual
Net Income
-$293.42M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.04M | 14.65M | 12.71M | 11.9M | 5.76M |
| Selling, General & Admin | 13.33M | 10.58M | 10.41M | 9.95M | 9.34M |
| Operating Expenses | 45.37M | 25.23M | 23.12M | 21.85M | 15.1M |
| Depreciation & Amortization | 101.79K | 8.51K | 30.98K | 22.47K | 5.44K |
| EBITDA | (45.28M) | (24.69M) | (21.69M) | 6.02M | (293.42M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (45.37M) | (25.23M) | (23.12M) | (21.85M) | (15.1M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 16.52K | 556.95K | 1.44M | 1.27M | 948.12K |
| Interest Expense | 6.33M | 7.41M | 8.28M | 4.56M | 0 |
| Other Income / Expenses | (6.34M) | (6.88M) | (6.89M) | 23.29M | (278.32M) |
| Income Before Tax | (51.71M) | (32.11M) | (30.01M) | 1.44M | (293.42M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (1.8M) | 0 | 0 | 0 | 0 |
| Net Income | (49.91M) | (32.11M) | (30.01M) | 1.44M | (293.42M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (9.35) | (6.01) | (4.61) | 0.19 | (34.67) |
| EPS (Diluted) | (9.35) | (6.01) | (4.61) | 0.19 | (34.67) |
| 5.34M | 5.34M | 6.51M | 7.57M | 8.46M | |
| 5.34M | 5.34M | 6.51M | 7.57M | 8.46M |
NERV Earnings Waterfall · TTM
NASDAQ:NERV · Revenue to Net Income
Key Ratios
EPS$-28.87
Gross Margin0.0%
Net Margin0.0%
P/E Ratio0.5
P/S Ratio0.0
Analysis
$0 of revenue converted into -$394.3M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-28.87, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 8-K | Current report | Nov 6, 2026 | |
| 10-Q | Quarterly report | Nov 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 | |
| SC 13G | SC 13G filing | Oct 27, 2026 |
How much revenue does NERV generate?
Minerva Neurosciences, Inc. (NERV) reported $0.00 of revenue in fiscal 2025.
Is NERV profitable?
Minerva Neurosciences, Inc. (NERV) reported -$293.42M of net income.
Continue the stock analysis
Jump to another research area for this company.